A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Mixed Q1 2026 Results And EU Trofinetide Setback

ACADIA Pharmaceuticals (ACAD) is back in focus after first quarter 2026 results showed 10% year over year revenue growth to US$268.1 million, alongside weaker earnings, higher expenses, and a setback for trofinetide in Europe.

See our latest analysis for ACADIA Pharmaceuticals.

The mixed Q1 2026 update, together with the negative EU opinion on trofinetide and leadership changes in research and development, appears to be feeding into a share price that has struggled year to date despite a strong 1 year total shareholder return of 33.28% and more modest 3 and 5 year total shareholder returns of 5.74% and 6.34%. This suggests momentum has cooled in the short term but remains positive over a longer horizon.

If ACADIA’s recent moves have you thinking about where growth in neurology and rare disease treatments could come from next, it may be worth scanning other healthcare related AI opportunities through the 35 healthcare AI stocks

With ACADIA trading at US$22.57 after a weak start to the year, but a 33.28% 1 year total return and an implied discount to some analyst targets, investors may be wondering whether there is still upside here or if future growth is already priced in.

Most Popular Narrative: 21.5% Undervalued

With ACADIA closing at $22.57 against a narrative fair value of $28.75, the most followed view sees meaningful upside baked into its specialized neurology focus.

From an investor standpoint, ACADIA’s challenge is balancing clinical ambition with financial discipline. Research and development costs remain elevated, and revenue concentration increases sensitivity to any disruption, whether regulatory, competitive, or reimbursement-related.

At the same time, success in even a limited number of indications can generate meaningful cash flow if adoption remains steady. This creates a setup where the downside is well understood, while the upside depends on disciplined execution rather than speculative breakthroughs.

Read the complete narrative.

What kind of revenue base and profitability does this narrative assume for ACADIA, and over what time frame? The full story connects sustained earnings growth, margin resilience, and a valuation multiple usually reserved for more diversified pharma players.

Result: Fair Value of $28.75 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, the story could shift quickly if key clinical programs disappoint or if heavy R&D and commercialization costs pressure margins more than this narrative assumes.

Find out about the key risks to this ACADIA Pharmaceuticals narrative.

Next Steps

If this mix of optimism and caution feels familiar, treat it as a prompt to review the data yourself and move quickly to your own judgment. To see what is currently driving the more optimistic side of the story, take a closer look at the 4 key rewards.

Looking for more investment ideas?

If ACADIA has sparked your interest, do not stop here. Broaden your watchlist with focused stock ideas that could suit very different goals and risk levels.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com